Daniel Worroll
Overview
Explore the profile of Daniel Worroll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galletti G, Halima A, Gjyrezi A, Zhang J, Zimmerman B, Worroll D, et al.
medRxiv
. 2024 Jul;
PMID: 38947080
One Sentence Summary: Transferrin Receptor identifies circulating tumor cells in solid tumors.
2.
Kim M, Chen C, Yaari Z, Frederiksen R, Randall E, Wollowitz J, et al.
Nat Chem Biol
. 2023 Jun;
19(12):1448-1457.
PMID: 37322156
Autophagy is a cellular process with important functions that drive neurodegenerative diseases and cancers. Lysosomal hyperacidification is a hallmark of autophagy. Lysosomal pH is currently measured by fluorescent probes in...
3.
Kim S, Au C, Jamalruddin M, Abou-Ghali N, Mukhtar E, Portella L, et al.
Elife
. 2022 Jul;
11.
PMID: 35848798
Expression of the AR splice variant, androgen receptor variant 7 (AR-V7), in prostate cancer is correlated with poor patient survival and resistance to AR targeted therapies and taxanes. Currently, there...
4.
Gjyrezi A, Galletti G, Zhang J, Worroll D, Sigouros M, Kim S, et al.
Commun Biol
. 2021 Jun;
4(1):785.
PMID: 34168263
Quantitation of androgen receptor variant (AR-V) expression in circulating tumor cells (CTCs) from patients with metastatic castration-resistant prostate cancer (mCRPC) has great potential for treatment customization. However, the absence of...
5.
Mukhtar E, Worroll D, Galletti G, Schuster S, Piha-Paul S, Giannakakou P
Cancer Drug Resist
. 2020 Oct;
3:636-646.
PMID: 33062959
Aim: We reviewed the radiographic response of three patients with metastatic castration-resistant prostate cancer treated with CRXL301, a docetaxel nanoparticle. For these three patients, we isolated and analyzed circulating tumor...
6.
Minuesa G, Albanese S, Xie W, Kazansky Y, Worroll D, Chow A, et al.
Nat Commun
. 2019 Jun;
10(1):2691.
PMID: 31217428
The MUSASHI (MSI) family of RNA binding proteins (MSI1 and MSI2) contribute to a wide spectrum of cancers including acute myeloid leukemia. We find that the small molecule Ro 08-2750...
7.
Worroll D, Galletti G, Gjyrezi A, Nanus D, Tagawa S, Giannakakou P
Phys Biol
. 2019 Feb;
16(3):036003.
PMID: 30763921
Androgen receptor (AR) signaling drives prostate cancer (PC) progression and remains active upon transition to castration resistant prostate cancer (CRPC). Active AR signaling is achieved through the nuclear accumulation of...
8.
Tagawa S, Antonarakis E, Gjyrezi A, Galletti G, Kim S, Worroll D, et al.
Clin Cancer Res
. 2018 Oct;
25(6):1880-1888.
PMID: 30301829
Purpose: Biomarkers aiding treatment optimization in metastatic castration-resistant prostate cancer (mCRPC) are scarce. The presence or absence of androgen receptor (AR) splice variants, AR-V7 and AR, in mCRPC patient circulating...
9.
Galletti G, Worroll D, Nanus D, Giannakakou P
J Cancer Metastasis Treat
. 2018 May;
3:190-205.
PMID: 29707651
The field of CTC enrichment has seen many emerging technologies in recent years, which have resulted in the identification and monitoring of clinically relevant, CTC-based biomarkers that can be analyzed...
10.
Antonarakis E, Tagawa S, Galletti G, Worroll D, Ballman K, Vanhuyse M, et al.
J Clin Oncol
. 2017 Jun;
35(28):3181-3188.
PMID: 28632486
Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance to taxanes...